RC2NB is excited to share the latest media coverage of one of our innovative international projects - Clinnova. This project focuses on revolutionizing autoimmune disease treatment through personalized medicine while ensuring data quality and protection using federated learning - a decentralized approach to AI training.
Clinnova consortium establishes Basel as the center of excellence for the region's multiple sclerosis (MS) treatment and highlights the close collaboration between our team, the University of Basel and the University Hospital Basel. The project, led by our co-CEO, Cristina Granziera, has received CHF 4 million in funding from the Basel Canton, benefiting patients and strengthening Basel's position in the global medical research community.
Project Highlights:
Personalized Treatment: Using AI, Clinnova will analyze large volumes of patient data to tailor therapies to individual needs, enhancing treatment efficacy and reducing side effects.
International Collaboration: The Clinnova consortium ensures data quality and protection through decentralized AI training, keeping patient data within local institutions while sharing insights globally.
Innovative Approach: Federated learning led by Bram Stieltjes will enable the development of algorithms that predict the best treatment options and timing for each patient, especially crucial for diseases like MS, known for its diverse manifestations.
We invite you to join us in sharing the news about this initiative that underscores Basel's role as a hub of medical excellence and innovation. Together, we are paving the way for a future where AI and personalized medicine transform healthcare.
Read the full article written by Agelika Jacobs to learn more about this remarkable project and the future of precision medicine here
